|
|
Blood, 1 February 2008, Vol. 111, No. 3, pp. 1584-1593.
Prepublished online as a Blood First Edition Paper on October 30, 2007; DOI 10.1182/blood-2007-09-112698.
 Previous Article | Next Article 
Submitted September 13, 2007
Accepted October 19, 2007
Comprehensive biomarker and genomic analysis identifies P53 status as the major determinant of response to MDM2 inhibitors in chronic lymphcytic leukemia
Chris Saddler, Peter Ouillette, Lisa Kujawski, Sanjeev Shangary, Moshe Talpaz, Mark Kaminski, Harry Erba, Kerby Shedden, Shaomeng Wang, and Sami N Malek*
Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, United States
Department of Statistics, University of Michigan, Ann Arbor, MI, United States
* Corresponding author; email: smalek{at}med.umich.edu.
Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world and remains incurable with conventional therapies. Patients with relapsed or resistant CLL have a significantly shortened lifespan.
MDM2 inhibitors have been developed and may have significant potential in the treatment of CLL. Clinical development of these compounds would be aided through knowledge of molecular predictors of activity.
To understand determinants of sensitivity or resistance to MDM2 inhibitor therapy in CLL, we comprehensively analyzed a large cohort of CLL patient-derived samples for response to MDM2 inhibition and correlated these responses with clinically important biomarkers. Furthermore, we employed high-density SNP arrays to analyze genome-wide changes of copy number and allele status, including that of p53.
The results of these studies conclusively demonstrate that p53 status is the major determinant of response to MDM2 inhibitors in CLL. Additional defects in the p53 regulatory cascade do not appear operational in this leukemia.
Further, we identify a novel subgroup of CLL patients with early progressive disease that appears particularly sensitive to MDM2 inhibitor treatment.
These data provide definitive evidence for target-specific and predictive activity and a rationale to proceed with this potentially important class of compounds in the treatment of CLL.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Articles in Blood Online:
-
SNP309 as predictor for sensitivity of CLL cells to the MDM2 inhibitor nutlin-3a
- Irina Seyfried, Sebastian Hofbauer, Markus Stoecher, Richard Greil, and Inge Tinhofer
Blood 2008 112: 2168.
[Full Text]
[PDF]
-
MDM2-SNP 309 allele status does not affect sensitivity to MDM2 inhibitors in CLL
- Sami N. Malek
Blood 2008 112: 2169.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
I. Seyfried, S. Hofbauer, M. Stoecher, R. Greil, and I. Tinhofer
SNP309 as predictor for sensitivity of CLL cells to the MDM2 inhibitor nutlin-3a
Blood,
September 1, 2008;
112(5):
2168 - 2168.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. N. Malek
MDM2-SNP 309 allele status does not affect sensitivity to MDM2 inhibitors in CLL
Blood,
September 1, 2008;
112(5):
2169 - 2169.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Kujawski, P. Ouillette, H. Erba, C. Saddler, A. Jakubowiak, M. Kaminski, K. Shedden, and S. N. Malek
Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia
Blood,
September 1, 2008;
112(5):
1993 - 2003.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Shangary, D. Qin, D. McEachern, M. Liu, R. S. Miller, S. Qiu, Z. Nikolovska-Coleska, K. Ding, G. Wang, J. Chen, et al.
Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition
PNAS,
March 11, 2008;
105(10):
3933 - 3938.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
